Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling of triple-negative breast cancer cells and liver cancer cells perturbed by BET inhibitor JQ1

ABSTRACT: To obtain the gene expression profiles of triple-negative breast cancer MDA-MB-231 cells and liver cancer HepG2 cells perturbed by the BET inhibitor JQ1, we treated MDA-MB-231 and HepG2 cells with either DMSO (control) or 10 μM JQ1 for 24 hours. By comparing the expression profiles of DMSO-treated cells with those treated with JQ1, we can identify the genes affected by JQ1.

ORGANISM(S): Homo sapiens

PROVIDER: GSE294293 | GEO | 2025/08/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression change after JQ1 treatment in breast cancer cell

Project description:BET bromodomain inhibitors effectively kill several types of cancer cells. However, the underlying mechanism of BET inhibition resistance remains obscure. We sought to identify the gene expression change upon treatment of JQ1, a well-known BET inhibitor, in basal-like breast cancer cells. In this dataset, we used RNA-sequencing to characterize the mRNA expression profiles from DMSO and JQ1-treated MDA-MB-231 breast tumor cells.

2019-11-07 | GSE140003 | GEO

Proteomics of Triple Negative Breast Cancer Cells Treated with SU056

Project description:1. Quantitative Proteomics: MDA-MB-231, MDA-MB-468, and MCF12A cells were treated with DMSO (vehicle control) or SU056 (novel small molecule drug candidate). Quantitative proteomics analysis was performed on cell lysates. 2. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 cells were treated with DMSO or SU056 and incubated at different temperatures and protein differences in the resulting soluble and insoluble fractions were determined.3. Cellular Thermal Shift Assay (CETSA): MDA-MB-231 YBOX1 KD cells were treated with DMSO or SU056 and incubated at different temperatures and protein differences in the soluble fractions were determined.

2024-04-04 | PXD042380 | Pride

Roscovitinen suppresses TRIM32 nuclear translocaton via STAT3 signaling

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of MDA-MB-231 cells treated with Roscovitinen and DMSO

2024-07-25 | GSE210030 | GEO

Effect of the BET inhibitor, JQ1, on gene expression in triple-negative breast cancer cell lines

Project description:To study the effect of BET inhibition on gene expression in triple-negative breast cancer cells, we treated MDA-MB-231 and HCC70 cells with vehicle or the prototypical BET inhibitor, JQ1, for 72 hours. By comparing the expression profiles of vehicle-treated versus JQ1-treated cells, we can identify genes that respond to BET inhibition. The Affymetrix Human Gene 2.0. St Microarray were processed with RMA (robust multichip average algorithm) as implemented in Bioconductor package oligo, where background subtraction, quantile normalization and summarization (via median-polish) was accomplished. The top differentially expressed genes were identified using empirical Bayesian procedure of limma package. FDR method was selected to adjust the p-values for multiple testing.

2019-03-16 | GSE79332 | GEO

m6A methylome in JQ1 treatment and control in MDA-MB-231 cells.

Project description:m6A methylome in JQ1 treatment and control in MDA-MB-231 cells.

| PRJNA907371 | ENA

Spatially Constrained Tandem Bromodomain Inhibition Bolsters Sustained Repression of BRD4 Transcriptional Activity for TNBC Cell Growth

Project description:We performed RNA-seq of MDA-MB-231 cells that were treated with MS645 or JQ1 at 50 nM and 500 nM in an effort to understand how MS645 exerts such a profound cell growth inhibition on cancer cells.

2018-08-31 | GSE115550 | GEO

RNA-sequencing of MDA-MB-231 breast cancer cells with and without treatment of BAY 2506856

Project description:MDA-MB-231 cancer cells were treated for 24h with DMSO or BAY 2506856. RNA-sequencing was performed to identify changes induced by treatment on the transcriptome level.

2024-02-01 | GSE243122 | GEO

Novel azetidine-based Stat3 inhibitors induce misfolded protein response, endoplasmic reticulum stress and mitophagy, and inhibit breast tumor growth in vivo

Project description:To identify differentially expressed genes and pathways in human breast cancer cell line MDA-MB-231 cells that are treated with a novel Stat3 inhibitor or DMSO control.

2022-07-12 | GSE180123 | GEO

BRD4 ChIP-seq in JQ1 treatment and control in MDA-MB-231 cells.

Project description:BRD4 ChIP-seq in JQ1 treatment and control in MDA-MB-231 cells.

| PRJNA907373 | ENA

Expression data from MDA-MB-231 breast cancer cell lines exposed to DMSO control and UF010

Project description:Breast cancer cell line MDA-MB-231 was treated with DMSO or UF010, a novel HDAC inhibitor for 24 hours. The impact of UF010 treatment on global gene expression was determined. We used Affymetrix Human Transcriptome Array 2.0 (HTA-2_0) to analyze genes that were up or downregulated upon UF010 exposure. MDA-MB-231 cells were treated with DMSO (control) or 1.0 ÂµM of UF010 for 24 hours.Total RNAs were isolated for hybridization on Affymetrix microarrays.

2015-02-19 | E-GEOD-56823 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data